How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,613 results for

Glucose Tolerance Test 3 hour

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. The oral glucose tolerance test (OGTT) revisited. (PubMed)

The oral glucose tolerance test (OGTT) revisited. The oral glucose tolerance test (OGTT) has been the mainstay for diagnosing diabetes for decades. Recently, the American Diabetes Association (ADA) suggested abandoning the OGTT, while resorting to a simpler screening test, exclusively based on baseline fasting blood glucose concentration. This review article rewinds the history of OGTT and its recent advancements, and compares its power in detecting early diabetes with that of fasting blood (...) glucose alone. The key point is that there are more diabetics originating from a population with normal fasting blood glucose than from subjects with impaired fasting glucose, those who can be detected by the new ADA recommendations. Conversely, the OGTT detects more efficiently early diabetes as well as subjects with IGT, as the glycemia at the second hour seems crucial as a diagnostic tool. We discuss the different significance of fasting versus second hour glycemia during OGTT, according

2011 European journal of internal medicine

182. Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs

to undergo a 2-hour oral glucose tolerance test (ingestion of 75g glucose with subsequent timed assessment of growth hormone, glucose, insulin and related binding proteins.) Baseline assessment of hormones that may contribute to the results will be drawn, prior to performing the test. Patients will be asked to complete one visit total to participate in this trial. Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 36 participants Observational Model (...) Tolerance Test (OGTT) An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood. Carcinoid Syndrome Patients carrying a diagnosis of carcinoid syndrome who are taking long-acting somatostatin for at least 3 months prior to study enrollment. Other: Oral Glucose Tolerance Test (OGTT) An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low

2011 Clinical Trials

183. Pioglitazone for diabetes prevention in impaired glucose tolerance. (PubMed)

patients were randomly assigned to receive pioglitazone or placebo. The median follow-up period was 2.4 years. Fasting glucose was measured quarterly, and oral glucose tolerance tests were performed annually. Conversion to diabetes was confirmed on the basis of the results of repeat testing.Annual incidence rates for type 2 diabetes mellitus were 2.1% in the pioglitazone group and 7.6% in the placebo group, and the hazard ratio for conversion to diabetes in the pioglitazone group was 0.28 (95 (...) % confidence interval, 0.16 to 0.49; P<0.001). Conversion to normal glucose tolerance occurred in 48% of the patients in the pioglitazone group and 28% of those in the placebo group (P<0.001). Treatment with pioglitazone as compared with placebo was associated with significantly reduced levels of fasting glucose (a decrease of 11.7 mg per deciliter vs. 8.1 mg per deciliter [0.7 mmol per liter vs. 0.5 mmol per liter], P<0.001), 2-hour glucose (a decrease of 30.5 mg per deciliter vs. 15.6 mg per deciliter

2011 NEJM Controlled trial quality: predicted high

184. Is one abnormal value on 3 hour oral glucose tolerance test associated with poor maternal and neonatal outcomes? A systematic review and meta-analysis

Is one abnormal value on 3 hour oral glucose tolerance test associated with poor maternal and neonatal outcomes? A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith (...) based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination

2015 PROSPERO

185. Effect of acacia polyphenol on glucose homeostasis in subjects with impaired glucose tolerance: A randomized multicenter feeding trial. (PubMed)

Effect of acacia polyphenol on glucose homeostasis in subjects with impaired glucose tolerance: A randomized multicenter feeding trial. Numerous in vitro and animal studies, as well as clinical trials have indicated that plant-derived polyphenols exert beneficial effects on glucose intolerance or type 2 diabetes. This clinical study aimed to investigate the effects of acacia polyphenol (AP) on glucose and insulin responses to an oral glucose tolerance test (OGTT) in non-diabetic subjects (...) with impaired glucose tolerance (IGT). A randomized, double-blind, placebo-controlled trial was conducted in a total of 34 enrolled subjects. The subjects were randomly assigned to the AP-containing dietary supplement (AP supplement; in a daily dose of 250 mg as AP; n=17) or placebo (n=17) and the intervention was continued for 8 weeks. Prior to the start of the intervention (baseline) and after 4 and 8 weeks of intervention, plasma glucose and insulin were measured during a two-hour OGTT. Compared

Full Text available with Trip Pro

2013 Experimental and therapeutic medicine Controlled trial quality: uncertain

186. A Comparison of the Oral and Intravenous Glucose Tolerance Tests in Non-Diabetic, Possible Diabetic and Diabetic Subjects (PubMed)

A Comparison of the Oral and Intravenous Glucose Tolerance Tests in Non-Diabetic, Possible Diabetic and Diabetic Subjects Results of standard three-hour oral glucose tolerance tests (OGTT) and intravenous glucose tolerance tests (IVGTT), performed on the same subjects, were compared in an attempt to determine their value in the diagnosis of borderline diabetes. A total of 83 such tests were carried out on 81 subjects. Applying the U.S. Public Health Service point count method to the results (...) of the OGTT test, there were 38 normals, 23 possible diabetics and 22 diabetics. A constant (K) was calculated from the glucose disappearance rate in the IVGTT curves.K disagreed with the OGTT classification to a significant extent, especially in the possible diabetic and non-diabetic groups. Also, the correlation coefficients between K and the OGTT values were not impressive. This does not mean that one test is superior to the other, only that the accuracy of either test in diagnosing early diabetes

Full Text available with Trip Pro

1964 Canadian Medical Association Journal

187. Elevated 1-h plasma glucose following 75-g oral glucose load is a predictor of arterial stiffness in subjects with normal glucose tolerance. (PubMed)

glucose tolerance test, only subjects with normal glucose tolerance were selected.One-hour post-challenge plasma glucose levels were correlated with brachial-ankle pulse wave velocity values (r = 0.340, P < 0.0001). When subjects with normal glucose tolerance were divided into three groups-group 1 (1-h plasma glucose < 8.56 mmol/l, n = 1595), group 2 (1-h plasma glucose ≥ 8.56 and < 10.17 mmol/l, n = 334) and group 3 (1-h plasma glucose ≥ 10.17 mmol/l, n = 130)-the brachial-ankle pulse wave velocity (...) of group 3 (1473 ± 322 cm/s) was significantly higher than that of group 2 (1355 ± 252 cm/s) and brachial-ankle pulse wave velocity of group 2 was also significantly higher than that of group 1 (1275 ± 212 cm/s).We have identified that, in normal glucose tolerance, arterial stiffness is advanced in subjects with higher 1-h post-challenge plasma glucose in spite of the normal range for BMI, systolic blood pressure, fasting plasma glucose and lipid variables. Higher 1-h plasma glucose level is a risk

2012 Diabetic Medicine

188. Prevalence of impaired glucose tolerance and diabetes after gestational diabetes mellitus comparing different cut-off criteria for abnormal glucose tolerance during pregnancy. (PubMed)

a 75g oral glucose tolerance test during pregnancy delivering in 2003-2005.At first follow-up, one to two years after delivery, 29% of eligible women with abnormal glucose tolerance during pregnancy had an oral glucose tolerance test - 160 with gestational diabetes and 309 with gestational impaired glucose tolerance - in addition to 167 control women. Cut-off levels defining gestational diabetes and impaired glucose tolerance were two-hour capillary blood glucose levels of 9.0 and 7.8mmol/l (...) or plasma glucose 10.0 and 8.6mmol/l, respectively.Frequency of abnormal test results at follow-up.Diabetes was diagnosed in 11% and impaired glucose tolerance in 24% of women with gestational diabetes vs. 4 and 23% in those with gestational impaired glucose tolerance, respectively. Combining women with abnormal test results during pregnancy revealed diabetes or impaired glucose tolerance in 29% as compared to 10% among controls; the odds ratio (95% confidence interval) for having abnormal test results

2011 Acta Obstetricia et Gynecologica Scandinavica

189. Adult Accuracy Study of the Enlite 3 Glucose Sensor

is a multi-center, randomized, in-clinic trial that aims to demonstrate the performance of the Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen and used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years with type 1 or type 2 diabetes for at least one year. Subjects are randomized into either Group A or Group B. The groups assigned will determine when the subject will be participating in the in-clinic YSI frequent sample testing (FST). For example on Day 1: Group (...) for at least one year. Device: Guardian Mobile App Device: 640G Insulin Pump Outcome Measures Go to Primary Outcome Measures : Enlite 3 Sensor Accuracy Mean Absolute Relative Difference (MARD) [ Time Frame: 7 Days ] Enlite 3 Sensor accuracy using two real time devices: 1) 640G Pump and 2) Guardian Mobile with the minimum calibration requirements (every 12 hours after the second calibration) will be evaluated. Enlite 3 Sensor values will be compared to YSI plasma glucose values, which is considered

2014 Clinical Trials

190. Chow fed UC Davis strain female Lepr fatty Zucker rats exhibit mild glucose intolerance, hypertriglyceridemia, and increased urine volume, all reduced by a Brown Norway strain chromosome 1 congenic donor region. (PubMed)

of the BN.ZUC-D1Rat183-D1Rat90 congenic strain to determine the specific characteristics of the UC Davis model. Fatty LeprfaSte/faSte animals of both BN and ZUC genotype in the congenic donor region had prediabetic levels of fasting blood glucose and blood glucose 2 hours after a glucose tolerance test. We observed significant congenic strain chromosome 1 genotype effects of the BN donor region in fatty females that resulted in decreased food intake, urine volume, glucose area under the curve during glucose (...) tolerance test, plasma triglyceride levels, and urine glucose excretion per day. In fatty females, there were significant congenic strain BN genotype effects on non-fasted plasma urea nitrogen, triglyceride, and creatinine. Congenic region genotype effects were observed by quantitative PCR of mRNA from the kidney for six genes, all located in the chromosome 1 BN donor region, with potential effects on T2D or kidney function. The results are consistent with the hypothesis that the BN genotype chromosome

Full Text available with Trip Pro

2017 PLoS ONE

191. Circulating C1q complement/TNF-related protein (CTRP) 1, CTRP9, CTRP12 and CTRP13 concentrations in Type 2 diabetes mellitus: In vivo regulation by glucose. (PubMed)

matched controls, and to examine the effects of a 2 hour 75g oral glucose tolerance test (OGTT) on serum CTRP1, CTRP9, CTRP12 and CTRP13 levels in persons with T2DM.Cross-sectional study [newly diagnosed T2DM (n = 124) and control (n = 139) participants]. Serum CTRP1, CTRP9, CTRP12 and CTRP13 were measured by ELISA.Systolic and diastolic blood pressure, total cholesterol (TCH), Low-density lipoprotein (LDL)-cholesterol, triglycerides, TCH/High-density lipoprotein (HDL) ratio, triglycerides/HDL ratio (...) Circulating C1q complement/TNF-related protein (CTRP) 1, CTRP9, CTRP12 and CTRP13 concentrations in Type 2 diabetes mellitus: In vivo regulation by glucose. The C1q complement/TNF-related protein (CTRP) superfamily, which includes the adipokine adiponectin, has been shown in animal models to have positive metabolic and cardiovascular effects. We sought to investigate circulating CTRP1, CTRP9, CTRP12 and CTRP13 concentrations in persons with type 2 diabetes mellitus (T2DM), with age and BMI

Full Text available with Trip Pro

2017 PLoS ONE

192. Pharmacokinetic Properties and Effects of PT302 After Repeated Oral Glucose Loading Tests in a Dose-Escalating Study. (PubMed)

(0.5, 1, 2, and 4 mg) was performed in 34 healthy individuals. The plasma concentrations of exenatide in serial blood samples were quantified for 56 days after dosing with an exendin-4 fluorescent immunoassay kit. Noncompartmental analysis was performed to assess the pharmacokinetic characteristics of PT302. Oral glucose tolerance tests were repeated weekly until day 42; the concentrations of serum glucose, serum C-peptide, plasma insulin, and plasma glucagon were measured for 2 hours to evaluate (...) Pharmacokinetic Properties and Effects of PT302 After Repeated Oral Glucose Loading Tests in a Dose-Escalating Study. PT302 is a sustained-release exenatide under clinical development for the treatment of type 2 diabetes mellitus.The aim of this study was to evaluate the pharmacokinetic properties, pharmacodynamic properties, and tolerability of PT302 after a single subcutaneous injection in healthy individuals.A dose-block randomized, double-blind, placebo-controlled, dose-escalating study

2014 Clinical therapeutics Controlled trial quality: uncertain

193. Common Variation at SLC16A11 and Other Genes on the Response to a Mixed Meal Tolerance Test

2 Secondary endpoints: change in fasting insulin, amino acid and lipid metabolites, GLP-1, and HOMA-IR from Visit 1 to Visit 2 Other Outcome Measures: Response to a Mixed Meal Tolerance Test after Metformin [ Time Frame: 2 hours after the meal ] Primary endpoint point: 2 hr glucose after the MMTT Secondary endpoints: 2 hr insulin after the MMTT, change in glucose, insulin, and amino acid and lipid metabolites from baseline to 60 and 120 minutes after the MMTT; glucose, insulin, and GLP-1 AUC (...) Date : March 2020 Estimated Study Completion Date : March 2020 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Carriers of the SLC16A11 risk allele Day 1: Mixed Meal Tolerance Test Day 3-7: 500mg metformin, twice daily Day 8: Mixed Meal Tolerance Test in presence of Metformin Other: Mixed Meal Tolerance Test The meal will provide a standard amount of total calories

2014 Clinical Trials

194. Acute effect of Ceylon cinnamon extract on postprandial glycemia: alpha-amylase inhibition, starch tolerance test in rats, and randomized crossover clinical trial in healthy volunteers. (PubMed)

been known for managing blood glucose. However, their effects on inhibiting digestion of carbohydrate have been poorly analyzed to date. The aim of this study was to investigate the acute effect of a specific Ceylon cinnamon hydro-alcoholic extract (CCE) on carbohydrate digestion and post-meal blood glucose reduction.In vitro enzymatic assays and in vivo starch tolerance tests in rats were designed as preclinical assays. Then, a randomized, double-blind, placebo-controlled, cross-over clinical (...) Acute effect of Ceylon cinnamon extract on postprandial glycemia: alpha-amylase inhibition, starch tolerance test in rats, and randomized crossover clinical trial in healthy volunteers. Postprandial hyperglycemia is a known risk factor for the development of several health disorders including type 2 diabetes, obesity, oxidative stress, and cardiovascular diseases. One encouraging approach for a better control of postprandial glycemia is to reduce carbohydrate digestion. Cinnamon extracts have

2014 BMC Complementary and Alternative Medicine Controlled trial quality: uncertain

195. Acute effect of Ceylon cinnamon extract on postprandial glycemia: alpha-amylase inhibition, starch tolerance test in rats, and randomized crossover clinical trial in healthy volunteers. (PubMed)

been known for managing blood glucose. However, their effects on inhibiting digestion of carbohydrate have been poorly analyzed to date. The aim of this study was to investigate the acute effect of a specific Ceylon cinnamon hydro-alcoholic extract (CCE) on carbohydrate digestion and post-meal blood glucose reduction.In vitro enzymatic assays and in vivo starch tolerance tests in rats were designed as preclinical assays. Then, a randomized, double-blind, placebo-controlled, cross-over clinical (...) Acute effect of Ceylon cinnamon extract on postprandial glycemia: alpha-amylase inhibition, starch tolerance test in rats, and randomized crossover clinical trial in healthy volunteers. Postprandial hyperglycemia is a known risk factor for the development of several health disorders including type 2 diabetes, obesity, oxidative stress, and cardiovascular diseases. One encouraging approach for a better control of postprandial glycemia is to reduce carbohydrate digestion. Cinnamon extracts have

Full Text available with Trip Pro

2014 BMC Complementary and Alternative Medicine Controlled trial quality: uncertain

196. One-hour post-load hyperglycemia combined with HbA1c identifies pre-diabetic individuals with a higher cardio-metabolic risk burden. (PubMed)

One-hour post-load hyperglycemia combined with HbA1c identifies pre-diabetic individuals with a higher cardio-metabolic risk burden. Evidence suggests that combining 1-hour plasma glucose ≥155 mg/dl during an oral glucose tolerance test (OGTT) with glycosylated hemoglobin (HbA1c) significantly increases their predictive power for incident diabetes, while their individual and joint associations with cardio-metabolic risk factors remain undefined. Herein, we evaluated whether 1-hour post-load (...) plasma glucose ≥155 mg/dl combined with HbA1c may identify pre-diabetic individuals with a higher cardio-metabolic risk.Anthropometric and metabolic characteristics, insulin sensitivity and insulin secretion assessed by OGTT-derived indexes, carotid intima-media thickness (IMT), pulse pressure, and rate pressure product were evaluated in 1495 individuals.As compared with subjects with 1-hour post-load glucose <155 mg/dl, individuals with 1-hour post-load glucose ≥155 mg/dl exhibited a significantly

2016 Atherosclerosis

197. One-hour post-load hyperglycemia confers higher risk of hepatic steatosis to HbA1c-defined pre-diabetic subjects. (PubMed)

One-hour post-load hyperglycemia confers higher risk of hepatic steatosis to HbA1c-defined pre-diabetic subjects. Individuals with glycated hemoglobin (HbA1c)-defined prediabetes (HbA1c value of 5.7-6.4%) and 1-hour plasma glucose ≥155 mg/dL during an oral glucose tolerance test have an increased risk of developing type 2 diabetes.To evaluate the degree to which HbA1c-defined prediabetes and 1-hour postload glucose ≥155 mg/dL individually and jointly associate with hepatic steatosis and related (...) biomarkers.A cross-sectional analysis was performed on 1108 White individuals.Ambulatory care.Anthropometric and metabolic characteristics including hepatic steatosis assessed by ultrasonography.Compared with the normal group (HbA1c <5.7%), HbA1c-defined prediabetic and diabetic individuals exhibit higher values of fasting, 1-hour, and 2-hour postload glucose; fasting and 2-hour postload insulin; triglycerides; uric acid; homeostasis model of assessment for insulin resistance; liver insulin resistance

Full Text available with Trip Pro

2016 Journal of Clinical Endocrinology and Metabolism

198. Guidelines for Blood Glucose Monitoring and Treatment of Hypoglycemia in Term and Late-Preterm Neonates

and may be harmful. 2. At-risk infants should be screened for hypoglycemia with a frequency and duration related to the speci?c risk factors of the individual infant. 3. Monitoring continues until normal, prefeed levels are consistently obtained. 4. Bedside glucose screening tests must be con?rmed by formal laboratory testing. Table 6. ManagementofDocumentedHypoglycemia A. Infant with no clinical signs 1. Continue breastfeeding (approximately every 1–2 hours) or feed 1–5mL/kg of expressed breastmilk (...) of 45mg/dL (2.5mmol/L) is indicated. PGL, plasma glucose level. a See Table 3. 174 ABM PROTOCOLinfants do not develop clinically signi?cant hypoglycemia simplyasaresultofatime-limiteddurationofunderfeeding. Testing methods Bedside glucose reagent test strips are inexpensive and practical but are not reliable, with signi?cant variance from true blood glucose levels, especially at low glucose concen- trations. 22,38,44–46 Bedside glucose tests may be used for screening, but laboratory levels sent STAT

2014 Academy of Breastfeeding Medicine

199. Dapagliflozin (Forxiga) in type 2 Diabetes Mellitus. Urinating glucose has its problems

of the human sodium-glucose co- transporter 2 (SGL T2), reducing glucose renal absorption and thus incrementing its excretion. It is rapidly absorbed after oral ingestion and reaches its peak plasma concentrations after 2 hours. The absolute oral bioavailability is 78%. Less than 2% is eliminated unaltered, and the rest is metabolized in the liver and kidney, pro- ducing an inactive metabolite that is eliminated mainly through renal excretion. Posology and administration 1 In monotherapy or combination (...) Dapagliflozin (Forxiga) in type 2 Diabetes Mellitus. Urinating glucose has its problems Forxiga® in type Diabetes Mellitus Urinating glucose has its problems Indications 1 In adult patients = 18 years with type 2 diabetes mellitus. Monotherapy. When diet and exercise alone do not provide adequate glycaemic con- trol in patients for whom use of metformin is considered inappropriate due to intolerance. Add-on combination therapy: In combination with other glucose-lowering medicinal pro- ducts

2014 Drug and Therapeutics Bulletin of Navarre (Spain)

200. Test almost all of your most important ECG rhythm interpretation skills with this case.

, and returned at 1400 (approximately 3 hours after presentation): Na = 118 K 7.2 Cl = 81 Bicarb = 12 Glucose = 209 Creatinine = 1.42 Anion Gap = 21 With the K now resulted, hyperkalemia was suspected and a repeat ECG was performed: The QRS is slightly wider still, with QRS duration 178 msec. PR interval is still 200 msec. No obvious change in T-wave morphology. This is mildly worse than presentation. At this point the patient received 2gm calcium gluconate, 500 mL lactated ringers, 40mg lasix IV, 10U (...) Test almost all of your most important ECG rhythm interpretation skills with this case. Dr. Smith's ECG Blog: Test almost all of your most important ECG rhythm interpretation skills with this case. Thursday, October 26, 2017 Sent by Anonymous, written by Meyers, edits by Smith: A female in her 70s with history of HTN woke up around 2am with severe shortness of breath. EMS found the patient in moderate respiratory distress, hypoxemic on room air, with diffuse rales. CPAP was initiated

2017 Dr Smith's ECG Blog

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>